Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast

Journal of Pathology

Volumn 187, Issue 3, 1999, Pages 279-284

  Vos, Carla B J ^a   Ter Haar, Natalja T ^a   Peterse, Johannes L ^b   Cornelisse, Cees J ^a   Van De Vijver, Marc J ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Breast cancer; Cyclin D1; DCIS; Gene amplification; ISH; Protein expression

Indexed keywords

CYCLIN D1; DNA; ESTROGEN RECEPTOR; PROTEIN;

ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; GENE; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOUTHERN BLOTTING;

BLOTTING, SOUTHERN; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CYCLIN D1; FEMALE; GENE EXPRESSION; GENES, BCL-1; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; NEOPLASM PROTEINS; RECEPTORS, ESTROGEN;

EID: 0032898624     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199902)187:3<279::AID-PATH240>3.0.CO;2-C     Document Type: Article

References (27)

1. Lidereau R, Callahan R, Dickson C, Peters G, Escot C, Ali I. Amplification of the int-2 gene in primary human breast tumors. Oncogene Res 1988; 2: 285-291.
2. Adnane J, Gaudray P, Simon M-P, Simon-Lafonaine J, Jeanteur P, Theillet C. Proto-oncogene amplification and human breast tumor phenotype. Oncogene 1989; 4: 1389-1395.
3. Tsuda H, Hirohashi S, Shimosato Y, et al. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units hst1/int-2 and c-erbB-2/ear1. Cancer Res 1989; 49: 3104-3108.
4. Fantl V, Richards MA, Smith R, et al. Gene amplification on chromosome band 11q13 and estrogen receptor status in breast cancer. Eur J Cancer 1990; 26: 423-429.
5. Theillet C, Adnarte J, Szepetowski P, et al. BCL-1 participates in the 11q13 amplification found in breast cancer. Oncogene 1990; 5: 147-149.
6. Lammi GA, Fantl V, Smith R, et al. D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 1991; 6: 439-444.
7. Schuuring E, Verhoeven E, Mooi WJ, Michalides RJAM. Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. Oncogene 1992; 7: 335-361.
8. Fantl V, Smith R, Brookes S, Dickson C, Peters G. Chromosome 11q13 abnormalities in human breast cancer. Cancer Surv 1993; 18: 77-94.
9. Peters G, Fantl V, Smith R, Brookes S, Dickson C. Chromosome 11q13 markers and D-type cyclins in breast cancer. Breast Cancer Res Treatment 1995; 33: 125-135.
10. Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J. Bernards R. Michalides RJAM. Cdk independent activation of estrogen receptor by cyclin Dl. Cell 1997; 88: 405-415.
11. Buckley MF, Sweeney KJ, Hamilton JA, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993; 8: 2127-2133.
12. Gillett C, Fantl V, Fisher C, et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994: 54: 1812-1817.
13. Worsley SD, Jennings BA, Khalil KH, Mole M, Girling AC. Cyclin D1 amplification and expression in human breast carcinoma: correlation with histological prognostic markers and oestrogen receptor expression J Clin Path Mol Pathol 1996; 49: M46-M50.
14. Weinstat-Saslow D, Merino MJ, Manrow RE, el al. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nature Med 1995; 12: 1257-1260.
15. Holland R, Peterse JL, Millis RR, et al. Ductal carcinoma in situ: a proposal for new classification. Semin Diagn Pathol 1994; 11: 167-180.
16. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: A Laboratory Manual. New York: Cold Spring Harbour Laboratory Press, 1989.
17. Willard HF, Smith KD, Sutherland J. Isolation and characterization of a major tandem repeat family from the human X-chromosome. Nucleic Acid Res 1983; 11: 2017-2033.
18. Vaandrager JW, Kluin PH, Schuuring E. The t(11;14)(q13;q32) in multiple myeloma cell line KM12 has its 11q13 breakpoint 330 kb centromeric from the cyclin D1 gene. Blood 1997; 89: 349-350.
19. Alers JC, Krijtenburg J, Vissers KJ, Bosnian FT, van der Kwast TH, van Dekken H. Interphase cytogenetics of prostatic adenocarcinomas and precursor lesions: analysis of 25 radical proslatectomies and 17 adjacent prostatic intra-epithelial neoplasias. Genes. Chromosomes Cancer 1995, 12: 241-250.
20. Adams JC. Biotin amplification of biotin and horseradish peroxidase signals in histochemical stains. J Hisiochem Cytochem 1992; 40: 1457-1463.
21. Young IT. Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources. J Histochem Cytochem 1977; 25: 935-944.
22. Simpson JF, Quan DE, O'Malley F, Odom-Maryon T, Clarke PE. Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast. Am J Pathol 1997; 161-168.
23. Silverstein MJ, Poller DN, Waisman JR, et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet 1995; 345: 1154-1157.
24. Misra DN, Dickman PS, Yunis EJ. Fluorescence in situ hybridization (FISH) detection of myc-N oncogene amplification in neuroblastoma using paraffin embedded tissue. Diagn Mol Pathol 1995; 4: 128-135.
25. Pauletti G, Godolphin W, Press MF, Slamon DJ Detection and quantitation of HER2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996; 13: 63-72.
26. Li BDL, Harlow SP, Budnick RM, Sheedy DL, Stewart CC. Detection of HER2/neu oncogene amplification in flow cytometry-sorted breast ductal cells by competitive polymerase chain reaction. Cancer 1994; 73: 2771-2778.
27. Deng GR, Yu M, Chen LC, et al. Amplification of oncogene erbb2 and chromosome 20q in breast cancer determined by differentially competitive polymerase chain reaction. Breast Cancer Res Treatment 1996; 40: 271-281.